amodiaquine has been researched along with Disease Models, Animal in 19 studies
Amodiaquine: A 4-aminoquinoline compound with anti-inflammatory properties.
amodiaquine : A quinoline having a chloro group at the 7-position and an aryl amino group at the 4-position.
Disease Models, Animal: Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Co-administration of amodiaquine with MAMA decoction (MD), an herbal antimalarial drug comprising the leaves of Mangifera indica L." | 7.83 | Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model. ( Adepiti, AO; Bolaji, OO; Elujoba, AA, 2016) |
| "To assess the relationship between the genetic and phenotypic factors linked to the cytochrome P-450 enzyme system and the response to the antimalarial drugs chloroquine, amodiaquine, mefloquine, and proguanil, as well as to determine how certain biological and social factors of the host influence the behavior of this enzymatic complex." | 4.83 | [Cytochrome P-450 and the response to antimalarial drugs]. ( Carmona-Fonseca, J; Guzmán, V, 2006) |
| "Co-administration of amodiaquine with MAMA decoction (MD), an herbal antimalarial drug comprising the leaves of Mangifera indica L." | 3.83 | Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model. ( Adepiti, AO; Bolaji, OO; Elujoba, AA, 2016) |
| "Amodiaquine (AQ) is associated with a relatively high incidence of idiosyncratic drug-induced liver injury (IDILI) and agranulocytosis." | 3.83 | Exploring an animal model of amodiaquine-induced liver injury in rats and mice. ( Cai, P; Li, J; Liu, F; Metushi, I; Nakayawa, T; Uetrecht, J; Vega, L, 2016) |
| "Amodiaquine is a widely used antimalarial in the countries that experience outbreaks of EVD and, therefore, holds promise as an approved drug that could be repurposed for treating EBOV infections." | 1.51 | In Vivo Activity of Amodiaquine against Ebola Virus Infection. ( DeWald, LE; Dowling, WE; Dyall, J; Eakin, AE; Gahagen, J; Gerhardt, DM; Green, CE; Hensley, LE; Holbrook, MR; Honko, AN; Huzella, L; Jahrling, PB; Janosko, K; Johnson, JC; Mirsalis, JC; Osborn, BL; Postnikova, E; Tang, L; Torzewski, LM, 2019) |
| " Administration of radiolabeled AQ in combination with BSO exhibited significantly higher covalent binding to mice liver proteins than that observed after sole dosing of radiolabeled AQ." | 1.35 | Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice. ( Aoki, T; Atsumi, R; Itokawa, K; Iwasaki, M; Izumi, T; Okazaki, O; Ono, C; Shimizu, S; Sudo, K, 2009) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (15.79) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (21.05) | 29.6817 |
| 2010's | 11 (57.89) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Monastyrskyi, A | 1 |
| Brockmeyer, F | 1 |
| LaCrue, AN | 1 |
| Zhao, Y | 1 |
| Maher, SP | 1 |
| Maignan, JR | 1 |
| Padin-Irizarry, V | 1 |
| Sakhno, YI | 1 |
| Parvatkar, PT | 1 |
| Asakawa, AH | 1 |
| Huang, L | 1 |
| Casandra, D | 1 |
| Mashkouri, S | 1 |
| Kyle, DE | 1 |
| Manetsch, R | 1 |
| DeWald, LE | 1 |
| Johnson, JC | 1 |
| Gerhardt, DM | 1 |
| Torzewski, LM | 1 |
| Postnikova, E | 1 |
| Honko, AN | 1 |
| Janosko, K | 1 |
| Huzella, L | 1 |
| Dowling, WE | 1 |
| Eakin, AE | 1 |
| Osborn, BL | 1 |
| Gahagen, J | 1 |
| Tang, L | 1 |
| Green, CE | 1 |
| Mirsalis, JC | 1 |
| Holbrook, MR | 1 |
| Jahrling, PB | 1 |
| Dyall, J | 1 |
| Hensley, LE | 1 |
| Jung, HY | 1 |
| Kim, B | 1 |
| Ryu, HG | 1 |
| Ji, Y | 1 |
| Park, S | 1 |
| Choi, SH | 1 |
| Lee, D | 1 |
| Lee, IK | 1 |
| Kim, M | 1 |
| Lee, YJ | 1 |
| Song, W | 1 |
| Lee, YH | 1 |
| Choi, HJ | 1 |
| Hyun, CK | 1 |
| Holzapfel, WH | 1 |
| Kim, KT | 1 |
| Mak, A | 1 |
| Cho, T | 1 |
| Uetrecht, J | 3 |
| Moon, M | 1 |
| Jung, ES | 1 |
| Jeon, SG | 1 |
| Cha, MY | 1 |
| Jang, Y | 1 |
| Kim, W | 1 |
| Lopes, C | 1 |
| Mook-Jung, I | 1 |
| Kim, KS | 3 |
| Kinoshita, K | 1 |
| Matsumoto, K | 1 |
| Kurauchi, Y | 1 |
| Hisatsune, A | 1 |
| Seki, T | 1 |
| Katsuki, H | 1 |
| Metushi, IG | 1 |
| Hayes, MA | 1 |
| Kim, CH | 1 |
| Han, BS | 1 |
| Moon, J | 1 |
| Kim, DJ | 1 |
| Shin, J | 1 |
| Rajan, S | 1 |
| Nguyen, QT | 1 |
| Sohn, M | 1 |
| Kim, WG | 1 |
| Han, M | 1 |
| Jeong, I | 1 |
| Lee, EH | 1 |
| Tu, Y | 1 |
| Naffin-Olivos, JL | 1 |
| Park, CH | 1 |
| Ringe, D | 1 |
| Yoon, HS | 1 |
| Petsko, GA | 1 |
| Abiodun, OO | 1 |
| Gbimadee, N | 1 |
| Gbotosho, GO | 1 |
| Adepiti, AO | 1 |
| Elujoba, AA | 1 |
| Bolaji, OO | 1 |
| Liu, F | 1 |
| Cai, P | 1 |
| Metushi, I | 1 |
| Li, J | 1 |
| Nakayawa, T | 1 |
| Vega, L | 1 |
| Walker, LA | 1 |
| Sullivan, DJ | 1 |
| Kiboi, DM | 1 |
| Irungu, BN | 1 |
| Langat, B | 1 |
| Wittlin, S | 1 |
| Brun, R | 1 |
| Chollet, J | 1 |
| Abiodun, O | 1 |
| Nganga, JK | 1 |
| Nyambati, VC | 1 |
| Rukunga, GM | 1 |
| Bell, A | 1 |
| Nzila, A | 1 |
| Shimizu, S | 1 |
| Atsumi, R | 1 |
| Itokawa, K | 1 |
| Iwasaki, M | 1 |
| Aoki, T | 1 |
| Ono, C | 1 |
| Izumi, T | 1 |
| Sudo, K | 1 |
| Okazaki, O | 1 |
| Guzmán, V | 1 |
| Carmona-Fonseca, J | 1 |
| Collins, WE | 1 |
| Sullivan, JS | 1 |
| Fryauff, DJ | 1 |
| Kendall, J | 1 |
| Jennings, V | 1 |
| Galland, GG | 1 |
| Morris, CL | 1 |
| Davidson, DE | 1 |
| Johnsen, DO | 1 |
| Tanticharoenyos, P | 1 |
| Hickman, RL | 1 |
| Kinnamon, KE | 1 |
| Nowak, JZ | 1 |
| Pilc, A | 1 |
| Wieczorek-Fila, Z | 1 |
| Maśliński, C | 1 |
| Cantrell, W | 1 |
| Elko, EE | 1 |
| Hopff, BM | 1 |
1 review available for amodiaquine and Disease Models, Animal
| Article | Year |
|---|---|
[Cytochrome P-450 and the response to antimalarial drugs].
Topics: Administration, Oral; Adult; Amodiaquine; Animals; Antimalarials; Biotransformation; Child; Chloroqu | 2006 |
18 other studies available for amodiaquine and Disease Models, Animal
| Article | Year |
|---|---|
Aminoalkoxycarbonyloxymethyl Ether Prodrugs with a pH-Triggered Release Mechanism: A Case Study Improving the Solubility, Bioavailability, and Efficacy of Antimalarial 4(1
Topics: Administration, Oral; Animals; Antimalarials; Cyclization; Disease Models, Animal; Ethers; Female; H | 2021 |
In Vivo Activity of Amodiaquine against Ebola Virus Infection.
Topics: Amodiaquine; Animals; Antiviral Agents; Artemisinins; Disease Models, Animal; Drug Combinations; Fem | 2019 |
Amodiaquine improves insulin resistance and lipid metabolism in diabetic model mice.
Topics: 3T3-L1 Cells; Amodiaquine; Animals; Antimalarials; Blood Glucose; Body Weight; Cell Proliferation; D | 2018 |
Use of an animal model to test whether non-alcoholic fatty liver disease increases the risk of idiosyncratic drug-induced liver injury.
Topics: Amodiaquine; Animals; Antibodies, Blocking; Chemical and Drug Induced Liver Injury; Choline Deficien | 2018 |
Nurr1 (NR4A2) regulates Alzheimer's disease-related pathogenesis and cognitive function in the 5XFAD mouse model.
Topics: Aging; Alzheimer Disease; Amodiaquine; Animals; Brain; Cognition; Disease Models, Animal; Glutamic A | 2019 |
A Nurr1 agonist amodiaquine attenuates inflammatory events and neurological deficits in a mouse model of intracerebral hemorrhage.
Topics: Amodiaquine; Animals; Cerebral Hemorrhage; Disease Models, Animal; Inflammation Mediators; Macrophag | 2019 |
Treatment of PD-1(-/-) mice with amodiaquine and anti-CTLA4 leads to liver injury similar to idiosyncratic liver injury in patients.
Topics: Amodiaquine; Animals; Antibodies; Chemical and Drug Induced Liver Injury; CTLA-4 Antigen; Disease Mo | 2015 |
Nuclear receptor Nurr1 agonists enhance its dual functions and improve behavioral deficits in an animal model of Parkinson's disease.
Topics: Amodiaquine; Animals; Behavior, Animal; Chloroquine; Disease Models, Animal; Ligands; Neurogenesis; | 2015 |
Lopinavir/ritonavir enhanced the antimalarial activity of amodiaquine and artesunate in a mouse model of Plasmodium berghei.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Artesunate; Disease Models, Animal; Drug Synergis | 2016 |
Evaluation of herbal antimalarial MAMA decoction-amodiaquine combination in murine malaria model.
Topics: Amodiaquine; Animals; Antimalarials; Chloroquine; Disease Models, Animal; Drug Resistance; Drug Ther | 2016 |
Exploring an animal model of amodiaquine-induced liver injury in rats and mice.
Topics: Agranulocytosis; Amodiaquine; Animals; Cells, Cultured; Chemical and Drug Induced Liver Injury; Cycl | 2016 |
Impact of Extended Duration of Artesunate Treatment on Parasitological Outcome in a Cytocidal Murine Malaria Model.
Topics: Amodiaquine; Animals; Antimalarials; Artemether; Artemisinins; Artesunate; Disease Models, Animal; F | 2017 |
Plasmodium berghei ANKA: selection of resistance to piperaquine and lumefantrine in a mouse model.
Topics: Amodiaquine; Animals; Antimalarials; Artemisinins; Chloroquine; Disease Models, Animal; Drug Resista | 2009 |
Metabolism-dependent hepatotoxicity of amodiaquine in glutathione-depleted mice.
Topics: Alanine Transaminase; Amodiaquine; Animals; Antimalarials; Buthionine Sulfoximine; Chemical and Drug | 2009 |
Adaptation of a chloroquine-resistant strain of Plasmodium vivax from Indonesia to New World monkeys.
Topics: Adaptation, Physiological; Adult; Amodiaquine; Animals; Antimalarials; Aotidae; Child; Chloroquine; | 2000 |
Evaluating new antimalarial drugs against trophozoite induced Plasmodium cynomolgi malaria in rhesus monkeys.
Topics: Amodiaquine; Animals; Antimalarials; Dapsone; Disease Models, Animal; Dose-Response Relationship, Dr | 1976 |
Effect of histidine on the formation of catalepsia-like symptoms in rats.
Topics: Amodiaquine; Anger; Animals; Catalepsy; Catatonia; Disease Models, Animal; Histidine; Humans; Inject | 1973 |
Plasmodium berghei: phagocytic hyperactivity of infected rats.
Topics: Amodiaquine; Animals; Carbon; Colloids; Disease Models, Animal; Malaria; Male; Organ Size; Phagocyto | 1970 |